Have a personal or library account? Click to login
Clinical Assessment of the Effect of Tetrabenazine on Functional Scales in Huntington Disease: A Pilot Open Label Study Cover

Clinical Assessment of the Effect of Tetrabenazine on Functional Scales in Huntington Disease: A Pilot Open Label Study

Tremor and Other Hyperkinetic Movements
Volume 2 (2012): Issue 0
By: Robert Fekete,  Anthony Davidson and  Joseph Jankovic  
Open Access
|Aug 2012

References

  1. 1
    JankovicJTreatment of hyperkinetic movement disordersLancet Neurol2009884485610.1016/S1474-4422(09)70183-819679276
    Back to article
  2. 2
    JankovicJClarence-SmithKTetrabenazine for the treatment of chorea and other hyperkinetic movement disordersExpert Rev Neurotherap2011111509152310.1586/ern.11.149
    Back to article
  3. 3
    Huntington Study GroupTetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trialNeurology20066636637210.1212/01.wnl.0000198586.85250.1316476934
    Back to article
  4. 4
    KollerWCTrimbleJThe gait abnormality of Huntington's diseaseNeurology1985351450145410.1212/WNL.35.10.14503162109
    Back to article
  5. 5
    BonelliRMMahnertFANiederwieserGOlanzapine for Huntington's disease: an open label studyClin Neuropharmacol200225263510.1097/00002826-200209000-0000712410058
    Back to article
  6. 6
    FerraraJMMostileGHunterCAdamORJankovicJEffect of tetrabenazine (TBZ) on motor function in patients with Huntington disease (HD)InProgram and abstracts of the 64th American Academy of Neurology Annual Meeting, Toronto, Ontario2010
    Back to article
  7. 7
    VidenovicABernardBFanWJaglinJLeurgansSShannonKMThe Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington's diseaseMov Disord20102540140410.1002/mds.2274820108371
    Back to article
  8. 8
    SteerRABallRRanieriWFBeckATDimensions of the Beck Depression Inventory-II in clinically depressed outpatientsJ Psychopathol Behav Assess199955117128
    Back to article
  9. 9
    Huntington Study GroupUnified Huntington's Disease Rating Scale: reliability and consistencyMov Disord19961113614210.1002/mds.8701102048684382
    Back to article
  10. 10
    BergKOMakiBEWilliamsJIet alClinical and laboratory measures of postural balance in an elderly populationArch Phys Med Rehabil199273107310801444775
    Back to article
  11. 11
    BergKOWood-DauphineeSLWilliamsJTMakiBMeasuring balance in the elderly: validation of an instrumentCan J Public Health199283S7111468055
    Back to article
  12. 12
    CohenJACutterGRFischerJSet alUse of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trialArch Neurol20015896196710.1001/archneur.58.6.96111405811
    Back to article
  13. 13
    JebsenRHTaylorNTrieschmannRBTrotterMJHowardLAAn objective and standardized test of hand functionArch Phys Med Rehabil1969503113195788487
    Back to article
  14. 14
    BeatonDEWrightJGKatzJNUpper extremity collaborative group. Development of the QuickDASH: Comparison of three item-reduction approachesJ Bone Joint Surg Am2005871038104610.2106/JBJS.D.0206015866967
    Back to article
  15. 15
    WhitneySLHudakMTMarchettiGFThe dynamic gait index relates to self-reported fall history in individuals with vestibular dysfunctionJ Vestib Res2000109910510939685
    Back to article
  16. 16
    TianJHerdmanSJZeeDSFolsteinSEPostural stability in patients with Huntington's diseaseNeurology1992421232123810.1212/WNL.42.6.12321534875
    Back to article
  17. 17
    SalomonczykDPanzeraRPirogovoskyEet alImpaired postural stability as a marker of premanifest Huntington's diseaseMov Disord2010252428243310.1002/mds.2330920818666
    Back to article
  18. 18
    ScholesKEHarrisonBJO'NeillBVet alAcute serotonin and dopamine depletion improves attentional control: findings from the Stroop TaskNeuropsychopharmacology2007321600161010.1038/sj.npp.130126217151596
    Back to article
  19. 19
    Sánchez-PernauteRKünigGdel Barrio AlbaAde YébenesJGVontobelPLeendersKLBradykinesia in early Huntington's diseaseNeurology20005411912510.1212/WNL.54.1.11910636136
    Back to article
  20. 20
    SmithMABrandtJShadmehrRMotor disorder in Huntington's disease begins as a dysfunction in error feedback controlNature200040354454910.1038/3500057610676962
    Back to article
  21. 21
    PaleacuDTetrabenazine in the treatment of Huntington's diseaseNeuropsychiatr Dis Treat2007354555119381278
    Back to article
  22. 22
    FrankSOndoWFahnSet alA study of chorea after tetrabenazine withdrawal in patients with Huntington diseaseClin Neuropharmacol20083112713310.1097/WNF.0b013e3180ca77ea18520979
    Back to article
  23. 23
    FrankSTetrabenazine as anti-chorea therapy in Huntington Disease: an open label continuation study. Huntington Study Group/TETRA-HD InvestigatorsBMC Neurology200996210.1186/1471-2377-9-6220021666
    Back to article
  24. 24
    SatouTAndersonAJItohTet alRepetitive administration of tetrabenazine induces irreversible changes in locomotion and morphology of substantia nigra in ratsExp Toxicol Pathol20015330330810.1078/0940-2993-0019511665855
    Back to article
  25. 25
    ButlerPDEdwardsEBarkaiIImipramine and tetrabenazine: effect on monoamine receptor binding sites and phosphoinositide hydrolysisEur J Pharmacol1989160931002540994
    Back to article
  26. 26
    ChafetzMDMatthewsLHA new interference score for the Stroop testArch Clin Neuropsychol20041955556710.1016/j.acn.2003.08.00415163456
    Back to article
DOI: https://doi.org/10.5334/tohm.91 | Journal eISSN: 2160-8288
Journal RSS Feed
Language: English
Submitted on: Dec 29, 2011
Accepted on: Oct 14, 2012
Published on: Aug 6, 2012
Published by: Columbia University Libraries/Information Services
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Tetrabenazine,
Huntington disease,
chorea

© 2012 Robert Fekete, Anthony Davidson, Joseph Jankovic, published by Columbia University Libraries/Information Services
This work is licensed under the Creative Commons License.

Previous articleVolume 2 (2012): Issue 0Next article